The U.S. FDA has approved Sanofi’s Dupixent (dupilumab) for the treatment of pediatric patients aged 1 to 11 years with eosinophilic esophagitis (EoE). Dupixent is now the first and only medicine approved in the U.S. specifically indicated to treat these patients.  This approval expands the initial FDA approval for EoE in May 2022 for patients aged 12 years and older. The FDA evaluated Dupixent for this expanded indication under Priority Review, which is reserved for medicines that repr...